Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J
NCT ID: NCT00899015
Last Updated: 2012-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
23 participants
OBSERVATIONAL
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is assessing arsenic trioxide in young patients with recurrent or refractory leukemia or lymphoma who were treated on clinical trial NCI-00-C-0070J.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
NCT00006091
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
NCT00003885
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
NCT00008697
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01835288
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
NCT00006092
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To assess the pharmacokinetic and pharmacodynamic profiles of arsenic trioxide in pediatric patients treated on protocol NCI-00-C-0070J.
OUTLINE: Bone marrow or peripheral blood mononuclear cells collected during treatment on NCI-00-C-0070J are assessed for pharmacodynamics studies. Plasma cells collected during treatment are assessed for pharmacokinetics studies. Total arsenic (As), inorganic As forms (AsIII and AsV), and methylated metabolites of As are assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pharmacological study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed leukemia or lymphoma refractory to standard curative treatment regimens
* No meningeal leukemia or lymphoma
* No HIV-related lymphoma
* No lymphoproliferative diseases
* Received treatment on protocol NCI-00-C-0070J
* Bone marrow or peripheral blood and serum samples collected during treatment on NCI-00-C-0070J are available
PATIENT CHARACTERISTICS:
* See NCI-00-C-0070J
PRIOR CONCURRENT THERAPY:
* See NCI-00-C-0070J
2 Years
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
National Institutes of Health Clinical Center (CC)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elizabeth Fox, MD
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-C-N221
Identifier Type: -
Identifier Source: secondary_id
CDR0000570658
Identifier Type: -
Identifier Source: secondary_id
999907221
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.